Search results for "Exudative macular detachment"

showing 1 items of 1 documents

Intravitreal Pegaptanib in Ischemic CRVO Refractory Exudative Macular Detachment

2012

Abstract Recent literature data reported evidence of the visual and/or anatomical benefits of all clinically available anti-VEGF drugs for the treatment of macular edema (ME) following Central Retinal Vein Occlusion (CRVO), up to 1-year followup. There are no randomized clinical trial data on anti-VEGF agents in ischemic CRVO-ME and the use of anti-VEGF agents to treat this condition. A 73-year old caucasian man, with a medical history of diabetes and systemic hypertension and an ophthalmic history of ischemic CRVO with cystoid macular edema was referred to our division on January 2011. The ophthalmic examination showed in right eye a visual acuity of 20/2000, a C2N1 cataract and an exudati…

medicine.medical_specialtyVisual acuitygenetic structuresPegaptanibIntravitreal pegaptanibCentral retinal vein occlusionOphthalmologymedicinePegaptanib SodiumExudative macular detachment; Central retinal vein occlusion; Intravitreal pegaptanibMedical historyMacular edemamedicine.diagnostic_testSettore MED/30 - Malattie Apparato Visivobusiness.industryCentral retinal vein occlusionExudative macular detachmentmedicine.diseaseFluorescein angiographyeye diseasesSurgerysense organsmedicine.symptomRanibizumabbusinessmedicine.drugJournal of Clinical & Experimental Ophthalmology
researchProduct